Sustained Ophthalmic Therapies Pave the Future for Ocular Therapeutix
Amarpreet Sawhney, President & CEO for Ocular Therapeutix, shares the company’s vision of becoming the leading developer of sustained ophthalmic therapies. Striving to improve patient outcomes, Amarpreet details the company’s proprietary technology that works across the front, back and surface of the eye.
Amar Sawhney, PhD
Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the Board in 2014. Dr. Sawhney served as CEO of Augmenix, from 2008 until 2014 and is a general partner of Incept, LLC, an intellectual property holding company.